Luxembourg-based biotechnology company Creabilis Therapeutics secured €15m ($20m) on Tuesday in a series B round led by Abbott Biotech Ventures, the corporate venturing unit for healthcare company Abbott Laboratories.
Abbott was joined by investment firm Neomed, venture capital firm Sofinnova Partners and unnamed private investors. Sofinnova and Neomed previously backed Creabilis’ €20m series A round in June 2008.
Eliot Forster, chief executive officer of Creabilis, said: "This new funding reflects the medical importance and significant commercial potential of our drugs…
